Clinical and Laboratory Characteristics of Sickle Cell Anemia Patients Admitted With Fever

August 25, 2011 updated by: Dr Koren Ariel, HaEmek Medical Center, Israel

Study the Clinical and Laboratory Characteristics and the Outcome of Sickle Cell Anemia Patients Admitted to the Pediatric Ward Because of Fever as the Presenting Symptom

This study will summarized the clinical and laboratory data and the outcome of all the patients suffering from Sickle Cell Anemia (Including Sickle cell thalassemia) admitted to the pediatric ward.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The actual protocol for SCA patients admitted with fever is to obtain blood cultures and start empiric antibiotic treatment.

The study cohort included 60 SCA patients actually treated in the Pediatric Hematology Unit.

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Israel
      • Afula, Israel, 18101
        • Pediatric Hematology Unit - Ha'Emek Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

60 patients treated at the Pediatric Hematology Unit in the Ha'Emek Medical Center suffering from sickle cell anemia or sickle cell thalassemia admitted with fever as the presenting symptom.

Description

Inclusion Criteria: All patients admitted with fever as the only presenting symptom.

Exclusion Criteria: Patients admitted with another causes related or unrelated to sickle cell disease and have also fever.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
1
Sickle cell anemia
Other: Observational
Summary of clinical and laboratory data
2
Sickle cell thalassemia
Other: Observational
Summary of clinical and laboratory data

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

HaEmek Medical Center, Israel

Investigators

  • Principal Investigator: Carina Levin, MD, Pediatric Hematology Unit - Ha'Emek Medical Center - Afula - 18101 - Israel
  • Principal Investigator: Ilena Arshinov, MD, Pediatric Dpt B - Ha'Emek Medical Center - Afula - Israel

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2008

Study Completion (Actual)

November 1, 2008

Study Registration Dates

First Submitted

August 14, 2008

First Submitted That Met QC Criteria

August 14, 2008

First Posted (Estimate)

August 15, 2008

Study Record Updates

Last Update Posted (Estimate)

August 26, 2011

Last Update Submitted That Met QC Criteria

August 25, 2011

Last Verified

August 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0027-08-EMC

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sickle Cell Anemia

Clinical Trials on Observational

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe